APOE ε4

APOE ε4
Name	Apolipoprotein E ε4
Organism	Homo sapiens
Gene	APOE
Location	Chromosome 19

APOE ε4 APOE ε4 is an allele of the human APOE gene encoding a variant of apolipoprotein E involved in lipid transport and neuronal maintenance. It is a major genetic risk modulator studied across Harvard University, University of Cambridge, National Institutes of Health, Wellcome Trust, Alzheimer's Research UK, and international consortia including the International Genomics Consortium and the European Alzheimer’s Disease Consortium. Research on this allele spans collaborations among investigators at institutions such as Massachusetts Institute of Technology, Stanford University, University College London, Columbia University, and McGill University.

Introduction

APOE ε4 is one of three common alleles at the APOE locus alongside alleles studied by teams at Johns Hopkins University, Yale University, University of California, San Francisco, University of Pennsylvania, and Imperial College London. Historical genetic mapping involved groups at Cold Spring Harbor Laboratory, Salk Institute, Broad Institute, Max Planck Institute for Biology, and Karolinska Institutet. Major population studies including cohorts from Framingham Heart Study, Rotterdam Study, UK Biobank, CARDIA Study, and Atherosclerosis Risk in Communities Study quantified its effects on cardiovascular and neurological phenotypes.

Genetics and molecular structure

The APOE ε4 allele differs by amino acid residues identified in sequencing projects by teams at Human Genome Project, Sanger Institute, Genentech, Roche, and Illumina. Structural characterization used methods developed at European Molecular Biology Laboratory, Lawrence Berkeley National Laboratory, Argonne National Laboratory, and cryo-EM groups at EMBL-EBI; these studies referenced protein structures resolved by researchers affiliated with University of Oxford and ETH Zurich. The allele encodes an apolipoprotein with altered receptor binding characterized using assays from labs at NIH Clinical Center, Mayo Clinic, Cleveland Clinic, and Mount Sinai Health System. Population genetics models incorporating data from University of Tokyo, Peking University, Seoul National University, and University of Cape Town helped trace haplotypes across human populations.

Epidemiology and population distribution

Epidemiological surveys conducted by World Health Organization, Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, Chinese Center for Disease Control and Prevention, and national biobanks reveal variable ε4 frequencies across regions studied by Australian National University, University of Auckland, University of São Paulo, University of Buenos Aires, and University of Nairobi. Ancient DNA projects involving Max Planck Institute for Evolutionary Anthropology, University of Copenhagen, University of Oxford, and Harvard Medical School tracked allele frequency shifts through migrations such as those documented at Neolithic Revolution and events studied in Viking Age population genetics. Large-scale meta-analyses by Consortium of Alzheimer’s Disease Genetics, Global Alzheimer’s Association Interactive Network, International Genomics Consortium, and teams at University of Toronto quantified associations with age, sex, and ancestry.

Association with Alzheimer's disease and other neurodegenerative disorders

Multiple landmark studies from Alzheimer's Disease Neuroimaging Initiative, National Institute on Aging, Rush University Medical Center, Duke University, and University of California, Los Angeles established APOE ε4 as a major risk allele for Alzheimer's disease and related dementias. Associations have been reported in clinical cohorts assembled by Memory and Aging Project, Framingham Heart Study, Rotterdam Study, Baltimore Longitudinal Study of Aging, and Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability. Links to Parkinson's disease, Lewy body dementia, traumatic brain injury cohorts studied at Walter Reed National Military Medical Center and University of Pennsylvania Perelman School of Medicine, and cerebrovascular disease were evaluated by collaborative networks including European Alzheimer’s Disease Consortium and Alzheimer's Disease Genetics Consortium.

Mechanisms of pathogenicity

Mechanistic research from groups at Scripps Research, Cold Spring Harbor Laboratory, Rockefeller University, Johns Hopkins University School of Medicine, and Gladstone Institutes implicates altered amyloid-beta metabolism, tau phosphorylation, synaptic dysfunction, lipid dysregulation, and neuroinflammation. Experimental systems developed at Jackson Laboratory, Stanford Neuroscience Institute, University of California, Berkeley, Princeton University, and University of Michigan used transgenic models, iPSC-derived neurons, and organoids to probe endosomal trafficking defects, microglial responses mediated by TREM2 pathways studied at Massachusetts General Hospital, and blood–brain barrier changes examined in studies from Karolinska Institutet and University of Zurich.

Clinical implications and testing

Clinical testing guidelines and ethical frameworks were influenced by recommendations from American College of Medical Genetics and Genomics, World Medical Association, National Society of Genetic Counselors, European Society of Human Genetics, and regulatory assessments at U.S. Food and Drug Administration. Genotyping services provided by companies like 23andMe, AncestryDNA, Illumina, Thermo Fisher Scientific, and academic clinical labs at Mayo Clinic Laboratories and Quest Diagnostics raise considerations for counseling at centers such as Genetic Counseling Program at Stanford and Columbia University Irving Medical Center. Risk communication strategies draw on models tested in trials at Johns Hopkins Bloomberg School of Public Health, King's College London, and University of Melbourne.

Therapeutic strategies and research directions

Interventional research spans monoclonal antibodies and small molecules developed by pharmaceutical firms including Biogen, Eli Lilly and Company, Roche, Novartis, AstraZeneca, and biotech startups funded by Bill & Melinda Gates Foundation and Wellcome Trust. Gene-editing and gene-silencing approaches leveraging CRISPR platforms from Broad Institute, CRISPR Therapeutics, Editas Medicine, and RNA therapies explored at Ionis Pharmaceuticals and Alnylam Pharmaceuticals are under investigation. Preventive and therapeutic trials coordinated by Global Alzheimer’s Platform Foundation, ClinicalTrials.gov, European Medicines Agency, and research centers at Mayo Clinic, Mount Sinai, UCSF Memory and Aging Center, and Banner Sun Health Research Institute explore personalized interventions integrating lipid-lowering agents, anti-inflammatory drugs, lifestyle measures studied in FINGER trial and neuroimaging biomarkers validated by ADNI.

Category:Genetics